Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2016

01.06.2016 | original report

Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer

verfasst von: Mathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, Anna S. Berghoff, Regina Promberger, Matthias Preusser, Peter Dubsky, Michael Gnant, Guenther G. Steger, Ansgar Weltermann, Christoph C. Zielinski, Otto Zach, Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Despite recent improvements, triple-negative breast cancer (TNBC) remains a breast cancer subtype with poor prognosis. TP53 mutations are commonly associated with TNBC, suggesting a role in breast cancer carcinogenesis. In addition to mutations, several reports focused on TP53 polymorphisms and their association with breast cancer risk and outcome. TP53 codon Pro72Arg polymorphism may predict response to anti-cancer therapy as Pro72 is apparently less effective in the induction of apoptosis.
Here, we investigated a potential association of TP53 mutations with TP53 codon 72 polymorphism and clinical outcome in a homogeneous cohort of TNBC patients.
DNA isolated from formalin-fixed paraffin-embedded tissue of 35 consecutive TNBC patients was investigated for TP53 mutation and TP53 codon 72 polymorphic status by Sanger sequencing.
The kind of TP53 mutations were associated with particular polymorphic Pro72Arg genotypes. Frameshift mutations were significantly correlated with Pro/Pro carriers, nonsense mutations showed a trend for Pro/Arg carriers. Despite this observation no association with clinical outcome was observed.
Further studies with larger and more homogeneous cohorts are warranted in order to elucidate a potential association of TP53 Pro72Arg polymorphism and particular TP53 mutations with TNBC carcinogenesis and outcome.
Literatur
1.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502.CrossRefPubMed Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502.CrossRefPubMed
2.
Zurück zum Zitat Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monographs. 2011;43:108–110.CrossRef Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monographs. 2011;43:108–110.CrossRef
3.
Zurück zum Zitat Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–629.CrossRefPubMed Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–629.CrossRefPubMed
4.
Zurück zum Zitat Walerych D, Napoli M, Collavin L, Sal G Del. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33(11):2007–2017.CrossRefPubMedPubMedCentral Walerych D, Napoli M, Collavin L, Sal G Del. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33(11):2007–2017.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Li T, Kon N, Jiang L, et al. Tumour suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence. Cell. 2012;149(6):1269–1283.CrossRefPubMedPubMedCentral Li T, Kon N, Jiang L, et al. Tumour suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence. Cell. 2012;149(6):1269–1283.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Själander A, Birgander R, Kivelä A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995;45(3):144–149.CrossRefPubMed Själander A, Birgander R, Kivelä A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995;45(3):144–149.CrossRefPubMed
8.
Zurück zum Zitat Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23(19):3328–3337.CrossRefPubMed Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23(19):3328–3337.CrossRefPubMed
9.
Zurück zum Zitat Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44(5):266–270.CrossRefPubMed Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44(5):266–270.CrossRefPubMed
10.
Zurück zum Zitat Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–884.CrossRefPubMed Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–884.CrossRefPubMed
11.
Zurück zum Zitat Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88(22):10124–10128.CrossRefPubMedPubMedCentral Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88(22):10124–10128.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Själander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1999;17(6):1313–1316.CrossRef Själander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1999;17(6):1313–1316.CrossRef
13.
Zurück zum Zitat Godai TI, Suda T, Sugano N, et al. Identification of colorectal cancer patients with tumours carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5‑fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer. 2009;2(9):420.CrossRef Godai TI, Suda T, Sugano N, et al. Identification of colorectal cancer patients with tumours carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5‑fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer. 2009;2(9):420.CrossRef
14.
Zurück zum Zitat Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.CrossRefPubMedPubMedCentral Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoural expression of BAX and p21, and increased breast cancer risk. PloS One. 2012;7(10):e47325.CrossRefPubMedPubMedCentral Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoural expression of BAX and p21, and increased breast cancer risk. PloS One. 2012;7(10):e47325.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39(Database Issue):D945–D950.CrossRefPubMed Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39(Database Issue):D945–D950.CrossRefPubMed
17.
Zurück zum Zitat Weston A, Godbold JH. Polymorphisms of H‑ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997;4:919–926.CrossRef Weston A, Godbold JH. Polymorphisms of H‑ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997;4:919–926.CrossRef
18.
Zurück zum Zitat Foedermayr M, Sebesta M, Rudas M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73(4):771–778.CrossRefPubMed Foedermayr M, Sebesta M, Rudas M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73(4):771–778.CrossRefPubMed
19.
Zurück zum Zitat Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumour suppressor gene: important milestones at the various steps of tumourigenesis. Genes Cancer. 2011;2(4):466–474.CrossRefPubMedPubMedCentral Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumour suppressor gene: important milestones at the various steps of tumourigenesis. Genes Cancer. 2011;2(4):466–474.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–358.PubMedPubMedCentral Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–358.PubMedPubMedCentral
21.
Zurück zum Zitat Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38.CrossRefPubMedPubMedCentral Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157–1167.CrossRefPubMed Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157–1167.CrossRefPubMed
23.
Zurück zum Zitat Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res. 2009;28:115.CrossRefPubMedPubMedCentral Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res. 2009;28:115.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat He XF, Su J, Zhang Y, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011;130(2):517–529.CrossRefPubMed He XF, Su J, Zhang Y, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011;130(2):517–529.CrossRefPubMed
25.
Zurück zum Zitat Langerød A, Bukholm IR, Bregård A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1684–1688.PubMed Langerød A, Bukholm IR, Bregård A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1684–1688.PubMed
26.
Zurück zum Zitat Dumont P, I‑Ju Leu J, Pietra AC Della, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–365.CrossRefPubMed Dumont P, I‑Ju Leu J, Pietra AC Della, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–365.CrossRefPubMed
27.
Zurück zum Zitat Wegman PP, Marcus NJ, Malakkaran BP, Wingren S. Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat. 2009;18(1):15–20.CrossRef Wegman PP, Marcus NJ, Malakkaran BP, Wingren S. Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat. 2009;18(1):15–20.CrossRef
Metadaten
Titel
Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer
verfasst von
Mathilde Foedermayr
Miriam Sebesta
Margaretha Rudas
Anna S. Berghoff
Regina Promberger
Matthias Preusser
Peter Dubsky
Michael Gnant
Guenther G. Steger
Ansgar Weltermann
Christoph C. Zielinski
Otto Zach
Rupert Bartsch
Publikationsdatum
01.06.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0261-9

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe